Press Release Distribution and Management
GlobeNewswire specializes in the distribution and delivery of press releases, financial disclosures and multimedia content to the media and general public.
www.globenewswire.comHere are the latest publicly available updates on CHARM Therapeutics:
- CHARM Therapeutics announced a Series B financing of $80 million, led by NEA and SR One, to advance its AI-designed menin inhibitor program for AML, with clinical development expected to start in Q1 2026. This press release was circulated in September 2025, marking a significant milestone for the company.[1]
- In the same period, CHARM shared progress on CHM-029, a next-generation menin inhibitor, highlighted as advancing in preclinical stages and designed to overcome resistance mutations; accompanying materials indicated plans for first-in-human studies, with formal announcements around late 2025 to 2026 window.[2]
- The company has maintained a public-facing news page detailing leadership appointments and strategic milestones, including prior C-suite hires and advisory board developments, with updated items appearing through 2025.[8]
If you’d like, I can summarize the most relevant points for a quick briefing or pull out key timelines and investor names for your records.
Would you like a concise timeline or a one-page briefing with risk and milestone highlights? I can also look for more recent press releases if needed.[1][2][8]